Astaxanthin inhibits expression of retinal oxidative stress and inflammatory mediators in streptozotocin-induced diabetic rats

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Yeh, Po Ting ^a,b   Huang, Hsin Wei ^c   Yang, Chung May ^a,b   Yang, Wei Shiung ^a,b   Yang, Chang Hao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 8 HYDROXYDEOXYGUANOSINE; ACROLEIN; ASTAXANTHIN; FRACTALKINE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXIREDOXIN; SODIUM CHLORIDE; STREPTOZOCIN; XANTHOPHYLL; ANTIOXIDANT; AUTACOID; GLUCOSE BLOOD LEVEL; MESSENGER RNA; PROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOWN REGULATION; DRUG MEGADOSE; ELECTRORETINOGRAPHY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; AQUEOUS HUMOR; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOLOGY; RETINA; RETINA GANGLION CELL;

ANIMALS; ANTIOXIDANTS; AQUEOUS HUMOR; BLOOD GLUCOSE; BODY WEIGHT; CHEMOKINE CCL2; DIABETES MELLITUS, EXPERIMENTAL; ELECTRORETINOGRAPHY; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; LUTEIN; NF-KAPPA B; OXIDATIVE STRESS; PROTECTIVE AGENTS; RATS; RETINA; RETINAL GANGLION CELLS; RNA, MESSENGER; XANTHOPHYLLS;

EID: 84955476733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0146438     Document Type: Article

References (60)

1. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic epidemiology. 2007; 14(4):179-83. doi: 10.1080/09286580701396720 PMID: 17896294.
2. Younis N, Broadbent DM, Harding SP, Vora JP. Incidence of sight-threatening retinopathy in Type 1 diabetes in a systematic screening programme. Diabetic medicine: a journal of the British Diabetic Association. 2003; 20(9):758-65. PMID: 12925058.
3. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010; 107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545 PMID: 21030723; PubMed Central PMCID: PMC2996922.
4. Kaneto H, Katakami N, Kawamori D, Miyatsuka T, Sakamoto K, Matsuoka TA, et al. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal. 2007; 9(3):355-66. doi: 10.1089/ ars.2007.9.ft-20 PMID: 17184181.
5. Pan HZ, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br J Ophthalmol. 2008; 92(4):548-51. doi: 10.1136/bjo.2007.130542 PMID: 18369071.
6. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996; 19(3):257-67. PMID: 8742574.
7. Anderson RE, Rapp LM, Wiegand RD. Lipid peroxidation and retinal degeneration. Curr Eye Res. 1984; 3(1):223-7. PMID: 6606531.
8. van Reyk DM, Gillies MC, Davies MJ. The retina: oxidative stress and diabetes. Redox Rep. 2003; 8 (4):187-92. doi: 10.1179/135100003225002673 PMID: 14599341.
9. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001; 158(1):147-52. doi: 10.1016/S0002-9440(10)63952-1 PMID: 11141487; PubMed Central PMCID: PMC1850259.
10. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004; 18(12):1450-2. doi: 10.1096/fj.03-1476fje PMID: 15231732.
11. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007; 2007:95103. doi: 10.1155/2007/95103 PMID: 18274606; PubMed Central PMCID: PMC2216058.
12. Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications. 2001; 15 (5):257-9. PMID: 11522500.
13. Harada C, Okumura A, Namekata K, Nakamura K, Mitamura Y, Ohguro H, et al. Role of monocyte chemotactic protein-1 and nuclear factor kappa B in the pathogenesis of proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2006; 74(3):249-56. doi: 10.1016/j.diabres.2006.04.017 PMID: 16730843.
14. Simo-Servat O, Hernandez C, Simo R. Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy. Mediators of inflammation. 2012; 2012:872978. doi: 10.1155/2012/ 872978 PMID: 23028204; PubMed Central PMCID: PMC3457631.
15. Kowluru RA, Koppolu P, Chakrabarti S, Chen S. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic Res. 2003; 37(11):1169-80. PMID: 14703729.
16. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes. 2001; 50(8):1938-42. PMID: 11473058.
17. Blokhina O, Virolainen E, Fagerstedt KV. Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann Bot. 2003; 91 Spec No:179-94. PMID: 12509339.
18. Kowluru RA, Kern TS, Engerman RL. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV. Antioxidant defense system. Free Radic Biol Med. 1997; 22(4):587-92. PMID: 9013121.
19. Jackson H, Braun CL, Ernst H. The chemistry of novel xanthophyll carotenoids. Am J Cardiol. 2008; 101(10A):50D-7D. doi: 10.1016/j.amjcard.2008.02.008 PMID: 18474275.
20. Kurashige M, Okimasu E, Inoue M, Utsumi K. Inhibition of oxidative injury of biological membranes by astaxanthin. Physiol Chem Phys Med NMR. 1990; 22(1):27-38. PMID: 2084711.
21. Ohgami K, Shiratori K, Kotake S, Nishida T, Mizuki N, Yazawa K, et al. Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest Ophthalmol Vis Sci. 2003; 44(6):2694-701. PMID: 12766075.
22. Ozawa Y, Sasaki M, Takahashi N, Kamoshita M, Miyake S, Tsubota K. Neuroprotective effects of lutein in the retina. Current pharmaceutical design. 2012; 18(1):51-6. PMID: 22211688; PubMed Central PMCID: PMC3319923.
23. Nakagawa K, Kang SD, Park DK, Handelman GJ, Miyazawa T. Inhibition of beta-carotene and astaxanthin of NADPH-dependent microsomal phospholipid peroxidation. J Nutr Sci Vitaminol (Tokyo). 1997; 43(3):345-55. PMID: 9268922.
24. Oshima S, Ojima F, Sakamoto H, Ishiguro Y, Terao J. Inhibitory effect of beta-carotene and astaxanthin on photosensitized oxidation of phospholipid bilayers. J Nutr Sci Vitaminol (Tokyo). 1993; 39(6):607-15. PMID: 8006717.
25. Spiller GA, Dewell A. Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial. J Med Food. 2003; 6(1):51-6. doi: 10.1089/109662003765184741 PMID: 12804020.
26. Stewart JS, Lignell A, Pettersson A, Elfving E, Soni MG. Safety assessment of astaxanthin-rich microalgae biomass: Acute and subchronic toxicity studies in rats. Food Chem Toxicol. 2008; 46(9):3030-6. doi: 10.1016/j.fct.2008.05.038 PMID: 18588938.
27. Nakajima Y, Inokuchi Y, Shimazawa M, Otsubo K, Ishibashi T, Hara H. Astaxanthin, a dietary carotenoid, protects retinal cells against oxidative stress in-vitro and in mice in-vivo. J Pharm Pharmacol. 2008; 60(10):1365-74. doi: 10.1211/jpp/60.10.0013 PMID: 18812030.
28. Naguib YM. Antioxidant activities of astaxanthin and related carotenoids. J Agric Food Chem. 2000; 48 (4):1150-4. PMID: 10775364.
29. Fang IM, Yang CM, Yang CH, Chiou SH, Chen MS. Transplantation of induced pluripotent stem cells without C-Myc attenuates retinal ischemia and reperfusion injury in rats. Experimental eye research. 2013; 113:49-59. doi: 10.1016/j.exer.2013.05.007 PMID: 23726881.
30. Chen FT, Yang CM, Yang CH. The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina. PloS one. 2013; 8(5):e64262. doi: 10.1371/journal. pone.0064262 PMID: 23691186; PubMed Central PMCID: PMC3653862.
31. Li P, Xu X, Zheng Z, Zhu B, Shi Y, Liu K. Protective effects of rosiglitazone on retinal neuronal damage in diabetic rats. Current eye research. 2011; 36(7):673-9. doi: 10.3109/02713683.2011.572220 PMID: 21599458.
32. Tanito M, Nishiyama A, Tanaka T, Masutani H, Nakamura H, Yodoi J, et al. Change of redox status and modulation by thiol replenishment in retinal photooxidative damage. Investigative ophthalmology & visual science. 2002; 43(7):2392-400. PMID: 12091442.
33. Chen FT, Liu YC, Yang CM, Yang CH. Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats. Investigative ophthalmology & visual science. 2012; 53(7):3682-94. doi: 10.1167/iovs.12-9505 PMID: 22538426.
34. Yang CH, Fang IM, Lin CP, Yang CM, Chen MS. Effects of the NF-kappaB inhibitor pyrrolidine dithiocarbamate on experimentally induced autoimmune anterior uveitis. Investigative ophthalmology & visual science. 2005; 46(4):1339-47. doi: 10.1167/iovs.04-0640 PMID: 15790900.
35. Matata BM, Galinanes M. Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor-kappa B DNA binding activity. J Biol Chem. 2002; 277(3):2330-5. doi: 10.1074/jbc.M106393200 PMID: 11706022.
36. Higuera-Ciapara I, Felix-Valenzuela L, Goycoolea FM. Astaxanthin: a review of its chemistry and applications. Critical reviews in food science and nutrition. 2006; 46(2):185-96. doi: 10.1080/ 10408690590957188 PMID: 16431409.
37. Hussein G, Sankawa U, Goto H, Matsumoto K, Watanabe H. Astaxanthin, a carotenoid with potential in human health and nutrition. Journal of natural products. 2006; 69(3):443-9. doi: 10.1021/np050354+ PMID: 16562856.
38. Izumi-Nagai K, Nagai N, Ohgami K, Satofuka S, Ozawa Y, Tsubota K, et al. Inhibition of choroidal neovascularization with an anti-inflammatory carotenoid astaxanthin. Invest Ophthalmol Vis Sci. 2008; 49 (4):1679-85. doi: 10.1167/iovs.07-1426 PMID: 18385091.
39. Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol. 2008; 101(10A):58D-68D. doi: 10.1016/j. amjcard.2008.02.010 PMID: 18474276.
40. Shen H, Kuo CC, Chou J, Delvolve A, Jackson SN, Post J, et al. Astaxanthin reduces ischemic brain injury in adult rats. FASEB J. 2009; 23(6):1958-68. doi: 10.1096/fj.08-123281 PMID: 19218497; PubMed Central PMCID: PMC2698661.
41. Wu TH, Liao JH, Hou WC, Huang FY, Maher TJ, Hu CC. Astaxanthin protects against oxidative stress and calcium-induced porcine lens protein degradation. J Agric Food Chem. 2006; 54(6):2418-23. doi: 10.1021/jf052651q PMID: 16536628.
42. Uchiyama K, Naito Y, Hasegawa G, Nakamura N, Takahashi J, Yoshikawa T. Astaxanthin protects beta-cells against glucose toxicity in diabetic db/db mice. Redox Rep. 2002; 7(5):290-3. PMID: 12688512.
43. Manabe E, Handa O, Naito Y, Mizushima K, Akagiri S, Adachi S, et al. Astaxanthin protects mesangial cells from hyperglycemia-induced oxidative signaling. J Cell Biochem. 2008; 103(6):1925-37. doi: 10. 1002/jcb.21583 PMID: 17955498.
44. Speranza L, Pesce M, Patruno A, Franceschelli S, de Lutiis MA, Grilli A, et al. Astaxanthin treatment reduced oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 as a novel biological target. Marine drugs. 2012; 10(4):890-9. doi: 10.3390/md10040890 PMID: 22690149; PubMed Central PMCID: PMC3366681.
45. Suzuki Y, Ohgami K, Shiratori K, Jin XH, Ilieva I, Koyama Y, et al. Suppressive effects of astaxanthin against rat endotoxin-induced uveitis by inhibiting the NF-kappaB signaling pathway. Exp Eye Res. 2006; 82(2):275-81. doi: 10.1016/j.exer.2005.06.023 PMID: 16126197.
46. Yeh PT, Yang CM, Huang JS, Chien CT, Yang CH, Chiang YH, et al. Vitreous levels of reactive oxygen species in proliferative diabetic retinopathy. Ophthalmology. 2008; 115(4):734-7 e1. doi: 10.1016/j. ophtha.2007.05.041 PMID: 18177940.
47. Cutler RG. Oxidative stress profiling: part I. Its potential importance in the optimization of human health. Ann N Y Acad Sci. 2005; 1055:93-135. doi: 10.1196/annals.1323.027 PMID: 16387721.
48. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990; 186:464-78. PMID: 1978225.
49. Cukiernik M, Mukherjee S, Downey D, Chakabarti S. Heme oxygenase in the retina in diabetes. Curr Eye Res. 2003; 27(5):301-8. PMID: 14562166.
50. Cosso L, Maineri EP, Traverso N, Rosatto N, Pronzato MA, Cottalasso D, et al. Induction of heme oxygenase 1 in liver of spontaneously diabetic rats. Free Radic Res. 2001; 34(2):189-91. PMID: 11264895.
51. Exner M, Minar E, Wagner O, Schillinger M. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med. 2004; 37(8):1097-104. doi: 10.1016/j.freeradbiomed.2004.07 008 PMID: 15451051.
52. Kubo E, Singh DP, Fatma N, Akagi Y. TAT-mediated peroxiredoxin 5 and 6 protein transduction protects against high-glucose-induced cytotoxicity in retinal pericytes. Life Sci. 2009; 84(23-24):857-64. doi: 10.1016/j.lfs.2009.03.019 PMID: 19351539.
53. Ottaviano FG, Handy DE, Loscalzo J. Redox regulation in the extracellular environment. Circ J. 2008; 72(1):1-16. PMID: 18159092.
54. Holmgren A, Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun. 2010; 396(1):120-4. doi: 10.1016/j.bbrc.2010.03.083 PMID: 20494123.
55. Gromer S, Urig S, Becker K. The thioredoxin system-from science to clinic. Med Res Rev. 2004; 24 (1):40-89. doi: 10.1002/med.10051 PMID: 14595672.
56. Xue J, Thippegowda PB, Hu G, Bachmaier K, Christman JW, Malik AB, et al. NF-kappaB regulates thrombin-induced ICAM-1 gene expression in cooperation with NFAT by binding to the intronic NF-kappaB site in the ICAM-1 gene. Physiol Genomics. 2009; 38(1):42-53. doi: 10.1152/physiolgenomics. 00012.2009 PMID: 19351910; PubMed Central PMCID: PMC2696150.
57. Donadelli R, Abbate M, Zanchi C, Corna D, Tomasoni S, Benigni A, et al. Protein traffic activates NF-kB gene signaling and promotes MCP-1-dependent interstitial inflammation. Am J Kidney Dis. 2000; 36 (6):1226-41. doi: 10.1053/ajkd.2000.19838 PMID: 11096048.
58. Bhavsar PK, Sukkar MB, Khorasani N, Lee KY, Chung KF. Glucocorticoid suppression of CX3CL1 (fractalkine) by reduced gene promoter recruitment of NF-kappaB. FASEB J. 2008; 22(6):1807-16. doi: 10.1096/fj.07-094235 PMID: 18230685.
59. Hernandez C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simo R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabetic medicine: a journal of the British Diabetic Association. 2005; 22(6):719-22. doi: 10.1111/j. 1464-5491.2005.01538.x PMID: 15910622.
60. Kowluru RA, Kanwar M, Chan PS, Zhang JP. Inhibition of retinopathy and retinal metabolic abnormalities in diabetic rats with AREDS-based micronutrients. Archives of ophthalmology. 2008; 126(9):1266-72. doi: 10.1001/archopht.126.9.1266 PMID: 18779489.